Adult survivors of childhood cancer are known to be at increased risk of subsequent malignancy, but only limited data exist describing the incidence and risk factors for secondary renal carcinoma. Among 14 358 5-year survivors diagnosed between 1970 and 1986, we estimated standardized incidence ratios (SIRs) for subsequent renal carcinoma and identified associations with primary cancer therapy using Poisson regression. Twenty-six survivors were diagnosed with renal carcinoma (median = 22.6 years from diagnosis; range = 6.3-35.7 years), reflecting a statistically significant excess (SIR = 8.0, 95% confidence interval [CI] = 5.2 to 11.7) compared with the general population. Highest risk was observed among neuroblastoma survivors (SIR = 85.8, 95% CI = 38.4 to 175.2) and, in multivariable analyses, with renal-directed radiotherapy of 5 Gy or greater (relative risk [RR] = 3.8, 95% CI = 1.6 to 9.3) and platinum-based chemotherapy (RR = 3.5, 95% CI = 1.0 to 11.2). To our knowledge, this is the first report of an association between cisplatin and subsequent renal carcinoma among survivors of childhood cancer. J Natl Cancer Inst; 2013; 105:504-508 In the general population, renal carcinoma occurs at a median age of 64 years (1). Despite the rarity of renal cancer in individuals aged less than 40 years, cases of renal carcinoma have been reported among childhood cancer survivors (2-5), particularly those treated for neuroblastoma (6-10). Renal cell carcinoma associated with neuroblastoma is now recognized as a distinct entity in the World Health Organization renal tumor classification (11). Previous studies have suggested that renal carcinoma may develop as a consequence of radiotherapy exposure in childhood or as a result of underlying genetic predisposition (7). More recently, renal cancers associated with Xp11.2 translocations and TFE3 gene transfusions are thought to result after exposure to alkylating agents (12,13).
In the general population, renal carcinoma occurs at a median age of 64 years (1) . Despite the rarity of renal cancer in individuals aged less than 40 years, cases of renal carcinoma have been reported among childhood cancer survivors (2) (3) (4) (5) , particularly those treated for neuroblastoma (6) (7) (8) (9) (10) . Renal cell carcinoma associated with neuroblastoma is now recognized as a distinct entity in the World Health Organization renal tumor classification (11) . Previous studies have suggested that renal carcinoma may develop as a consequence of radiotherapy exposure in childhood or as a result of underlying genetic predisposition (7) . More recently, renal cancers associated with Xp11.2 translocations and TFE3 gene transfusions are thought to result after exposure to alkylating agents (12, 13) .
The cumulative incidence of renal carcinoma among survivors of childhood cancer is not established. Most studies have consisted of case reports or small case series (4, 6, 7, 9, 10, 13, 14) . In larger cohorts, subsequent renal carcinomas have generally been grouped with other neoplasms without specifying morphology, site, or associations with therapeutic exposures (15, 16) . Therefore, we describe the incidence of subsequent renal carcinoma in the Childhood Cancer Survivor Study (CCSS) and identify associations with primary diagnosis and treatment.
The CCSS is a retrospective cohort with longitudinal follow-up of 14 358 5-year childhood cancer survivors treated at 26 institu tions in the United States and Canada between 1970 and 1986. All protocol and contact documents were approved by the human subjects committee at each participating institution. Informed consent was obtained from all participants. The CCSS methodology has been previously described (17) . Therapeutic exposures were ascertained through abstraction of medical records. Absorbed doses of radiotherapy to the kidneys were estimated based on measurements in tissue-equivalent phantoms and calculations in a three-dimensional mathematical phantom (18) . Cases of renal carcinoma occurring 5 or more years after childhood cancer diagnosis were ascertained by self-report and confirmed by pathology report, medical record, or death certificate (International Classification of Diseases for Oncology 2 site code C64.9). The cumulative incidence was estimated from 5 years after diagnosis to the first occurrence of renal carcinoma, treating death as a competing risk and censoring at the date of last contact. Standardized incidence ratios (SIRs) were calculated using age-, sex-, and calendar-specific rates from the Surveillance, Epidemiology and End Results database. Poisson regression was used to assess associations between treatment characteristics and the risk of subsequent renal carcinoma using the age at end of follow-up as the exposure time to account for age dependence of risks. Multivariable analysis was limited to demographic and treatment variables with univariable associations statistically significant at P less than or equal to .05. Because survivors likely received different radiotherapy doses to each kidney, an additional model using each kidney as an observation, with a random effect for each person, was calculated for this association. All statistical tests were two-sided.
Among the 14 358 survivors (median age at end of follow-up = 32.1 years, range = 5.6-58.9 years; median follow-up from initial cancer = 24.3 years, range = 5-35.7 years), 26 were diagnosed with a subsequent renal carcinoma. Median time to diagnosis was 22.6 years (range = 6.3-35.7 years). The cumulative incidence was 0.16% (95% confidence interval [CI] = 0.08% to 0.24%) at 25 years after initial cancer diagnosis. The majority of survivors with renal carcinoma received chemotherapy, whereas 9 received radiation of 5 Gy or greater to either kidney (Table 1) .
Survivors were more likely to develop renal carcinoma than the general population (SIR = 8.0, 95% CI = 5.2 to 11.7) ( Table 2) , as were survivors of neuroblastoma (n = 8 cases among 954 survivors; SIR = 85.8, 95% CI = 38.4 to 175.2). The overall absolute excess risk was 8.4 per 10 5 person-years. In univariable models, increased risk was observed after exposure BRieF CommuniCAtion * Percentages for individual characteristics calculated on total number of participants providing information for those characteristics. AER = absolute excess risk; CI = confidence interval; CNS = central nervous system tumor; CCSS = Childhood Cancer Survivor Study; HL = Hodgkin lymphoma; NHL = Non-Hodgkin lymphoma; SIR = standardized incidence ratio. † SIRs were calculated by comparing rates of subsequent renal carcinoma within the CCSS to Surveillance, Epidemiology and End Results. The CCSS is a multicenter, hospital-based, cohort study. It is estimated to include approximately 40% to 45% of 5-year survivors of childhood cancer diagnosed between 1970 and 1986 in the United States (17) . ‡ AER per 100 000 person-years § Participants who received radiation of 5 Gy or greater to at least one or both of their kidneys were considered to have received renal radiation. For participants who underwent a complete nephrectomy, radiation dose to the remaining kidney was used to classify radiation exposure.
to cisplatin (relative risk [RR] = 3.8, 95% CI = 1.3 to 11.2) and radiotherapy of 5 Gy or greater to one or both kidneys (RR = 4.1, 95% CI = 1.7 to 9.8) (Supplementary Table 1 , available online). Survivors of neuroblastoma had a 15-fold (RR = 15.1, 95% CI = 4.0 to 57.4) increased risk when compared with survivors of leukemia. Age at diagnosis, sex, and other chemotherapeutic exposures was not associated with risk among survivors (P >.05). In multivariable analysis, increased risk was associated with renal-directed radiotherapy of 5 Gy or greater (RR = 3.8, 95% CI = 1.6 to 9.3) and cisplatin exposure (RR = 3.5, 95% CI = 1.0 to 11.2). When each kidney was assessed independently, the increased risk of renal carcinoma after radiotherapy of 5 Gy or greater (RR = 2.5, 95% CI = 0.9 to 7.5) did not achieve statistical significance.
In this study, we observed an increased risk of subsequent renal cancers associated with renal-directed radiotherapy, consistent with reports among survivors of adult cancers (19) (20) (21) . We also observed an unexpected increased risk after platinum exposure, independent of radiotherapy. Although previous studies in survivors of adult testicular and cervical cancer who received both platinum-based chemotherapy and testicular/pelvic irradiation reported increased risks for renal carcinoma (19) (20) (21) , these risks were largely attributed to the effects of radiotherapy. Nevertheless, chemotherapy including platinum-based agents has been associated with a twofold increased risk of a second solid tumor among survivors of testicular cancer when compared with those patients treated with surgery alone (22). Although the number of survivors who developed a renal carcinoma in this study is small, our findings warrant further investigations of the toxic effects of radiotherapy and platinum-based chemotherapy on the long-term renal health of childhood cancer survivors as they age through adulthood.
Our observation of an elevated risk of renal cancer among survivors of neuroblastoma is consistent with numerous prior case reports and series (6) (7) (8) (9) (10) . In addition, two cases of subsequent renal cancer were reported in our study by survivors with tuberous sclerosis, a familial condition predisposing them to an increased risk of cancer, which may suggest an underlying role for genetic predisposition.
A limitation of this study was the use of self-report questionnaires to initially identify potential cases of renal carcinoma in the CCSS. Potential underreporting by participants may bias the results by underestimating the rate of renal carcinoma among survivors. Further, evaluation of associations with cancer therapy was restricted by the limited number of cases identified. Although tumor specimens were not obtained in this study, future investigations should evaluate the presence of cytogenetic abnormalities.
In summary, survivors of childhood cancer are at increased risk of subsequent renal cancers compared with the general population, with highest risks observed among survivors of neuroblastoma and after irradiation involving the kidneys. Future studies should monitor the incidence and validate the association with cisplatin as this population ages. 
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